Definitive Healthcare Corp. Q1 FY2026 earnings call

• Life science segment: Claims data has returned to historical levels, with the worst of the claims disruption likely behind them. Using AI internally for engineering and development, in operational efficiencies, and in product with next-gen architecture leveraging AI to drive value. • CRPO: Driven by fewer multi-year deals and shift to single-year deals, with professional services revenue growing double-digit not reflected in CRPO. • Data partnership: Benefit from end of 24 fully anniversary now, no longer a compare element.

The life science segment had a broader decline, but the company has repaired the claims data set. Now above historical levels, expecting less down pressure on renewals. CRPO is affected by fewer multi-year deals and shift to single-year deals, with professional services revenue growing double-digit but not reflected in CRPO. The data partnership benefit from end of 24 is no longer a compare element.

• Total revenue expected to be roughly flat midpoint through remainder of year, with sequential increase at higher end of guide. • Expect to continue seeing CRPO declines for next several quarters due to deal duration mix. • Claims disruption not expected to be a headwind moving forward, but need to see next couple of quarters of renewals.

• The timing of claims data source acquisition didn't impact renewal decisions made in December and January. • Dependence on domain expertise and contextual expertise in healthcare which is complex and outside of full control.

Q: Elaborate on life science segment demand, win rate, and when claims disruption stops being a factor.

A: Claims data returned to historical levels, worst of disruption likely past. Core commercialization depends on R&D cycle.

Q: Talk about AI use in packaging data assets, client consumption, and ASP impact.

A: AI used internally, in operational efficiencies, and in product with next-gen architecture to drive value.

Q: Summarize dynamics affecting year-over-year compares on revenue margin, CRPO, RPO.

A: CRPO decline due to fewer multi-year deals, professional services revenue growth not in CRPO, data partnership benefit no longer a compare.

Q: When will CRPO comp out the deal duration mix?

A: Expect couple more quarters of this, then stabilization.

Q: Is claims disruption no longer a headwind in 26?

A: Claims data above historical, but need to see next quarters of renewals